Chelsea Therapeutics' arthritis treatment achieves 90% efficacy in six months

By Elaine Rigoli

Tampa, Fla., May 25 - Chelsea Therapeutics International, Ltd. said the results of a pilot clinical study of CH-1504, a metabolically stable antifolate, demonstrated striking efficacy, with 60% of patients responding to therapy within four weeks and 90% responding by the end of the six-month study.

This non-blinded, non-randomized trial compared CH-1504 to methotrexate (MTX), the current standard of care for rheumatoid arthritis, in 20 patients with advanced rheumatoid arthritis.

Chelsea added that CH-1504 showed no elevation in liver enzymes and a lack of gastrointestinal related side-effects, suggesting that it may possess an improved safety and tolerance profile compared to MTX.

Two groups of 10 patients with active rheumatoid arthritis were assigned to receive either 6.67 mg daily oral dosing of CH-1504 or 10 mg once weekly oral dosing of MTX for a period of 24 weeks.

This data was published in the May issue of the Journal of Rheumatology, an international, peer-reviewed publication.

Chelsea Therapeutics is a biopharmaceutical development company located in Charlotte, N.C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.